公开(公告)号：US20250084158A1

公开(公告)日：2025-03-13

申请号：US18580552

申请日：2022-07-20

Applicant: ABL BIO INC.

Inventor： Eunsil SUNG ,  Junga KWON ,  Youngkwang KIM ,  Juhee KIM ,  Kyungjin PARK ,  Sumyeong PARK ,  Byungje SUNG ,  Byeongmin YOO ,  Bora LEE ,  Suyoun LEE ,  Shinai LEE ,  Yangsoon LEE ,  Eunhee LEE ,  Yangmi LIM ,  Jaehyoung JEON ,  Jinwon JUNG

IPC: C07K16/24 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28

Abstract: Provided are anti-CLL-1 antibodies and uses thereof, according to the anti-CLL-1 antibody of one aspect, it can bind to CLL-1 with high binding affinity, and can cause activation of T cells, thus it can be used effectively for preventing or treating the cancer expressing CLL-1.

公开(公告)号：US12071483B1

公开(公告)日：2024-08-27

申请号：US16770728

申请日：2018-12-14

Applicant: ABL Bio Inc.

Inventor： Jinhyung Ahn ,  Sungwon An ,  Dongin Kim ,  Eunsil Sung ,  Jaehyun Eom ,  Sang Hoon Lee ,  Weonkyoo You ,  Juhee Kim ,  Kyungjin Park ,  Hyejin Chung ,  Jinwon Jung ,  Bora Lee ,  Byungje Sung ,  Yeunju Kim ,  Yong-Gyu Son ,  Seawon Ahn ,  Daehae Song ,  Jiseon Yoo ,  Youngdon Pak ,  Donghoon Yeom ,  Yoseob Lee ,  Jaeho Jung

IPC: A61K39/395 ,  A61K47/68 ,  C07K16/18 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K47/6845 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567

Abstract: The present invention relates to a bi-specific antibody that specifically binds to alpha-synuclein and IGF1R, and use of the bi-specific antibody for treating or diagnosing synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates. The IGF1R portion of the bi-specific antibody acts as a shuttle to penetrate the blood brain barrier, allowing the alpha-synuclein portion to exert its action in the brain. Further, the half-life of the bi-specific antibody may be extended to maintain efficacy over time.

公开(公告)号：US11707533B2

公开(公告)日：2023-07-25

申请号：US16940326

申请日：2020-07-27

Applicant: LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

Inventor： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-Na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC: A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K47/6849 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2803

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US20230051266A1

公开(公告)日：2023-02-16

申请号：US17783344

申请日：2020-12-10

Applicant: ABL BIO INC.

Inventor： Kyung Jin PARK ,  Yang Soon LEE ,  Sae Yi LIM ,  Hye Jin CHUNG ,  Kyeong Su PARK ,  Yong Gyu SON ,  Seong Gyu SEON ,  Won Jun SON ,  Eun Jung KIM ,  Jae Hyun EOM ,  Ui Jung JUNG ,  Min Ji PARK ,  Jung Hyeon HONG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/46

Abstract: An anti-B-cell maturation antigen (BCMA)/anti-4-1BB bispecific antibody or an antigen-binding fragment thereof, and use thereof, are provided. The bispecific antibody or an antigen-binding fragment thereof may have high binding affinity to both of a BCMA protein and a 4-1BB protein and may be effectively used to prevent or treat a disease related to BCMA, 4-1BB, or both thereof (e.g., cancer).

公开(公告)号：US20220348665A1

公开(公告)日：2022-11-03

申请号：US17616799

申请日：2020-06-15

Applicant: ABL Bio Inc.

Inventor： Sungwon AN ,  Jinhyung AHN ,  Byungje SUNG ,  Dongin KIM ,  Daehae SONG ,  Jaehyun EOM ,  Yong-Gyu SON ,  Kyungjin PARK ,  Juhee KIM ,  Jinwon JUNG ,  Bora LEE ,  Hyesu YUN

IPC: C07K16/28 ,  C07K16/18 ,  A61P25/28

Abstract: The present disclosure relates to a bispecific antibody that specifically binds to alpha-synuclein and IGF1R, and an use of the bispecific antibody for the prevention, treatment and/or diagnosis of synucleinopathies associated with alpha-synuclein or alpha-synuclein aggregates, and can allow the alpha-synuclein antibody or an antigen-binding fragment thereof to penetrate the blood brain barrier to exert its action in the brain, and extend the half-life to maintain the efficacy for a long time.

公开(公告)号：US11261259B2

公开(公告)日：2022-03-01

申请号：US17286437

申请日：2020-08-12

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.